Tarsus Pharmaceuticals Inc (TARS) concluded trading on Wednesday at a closing price of $50.84, with 0.49 million shares of worth about $24.73 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 46.34% during that period and on November 27, 2024 the price saw a gain of about 2.38%. Currently the company’s common shares owned by public are about 34.21M shares, out of which, 32.56M shares are available for trading.
Stock saw a price change of 9.15% in past 5 days and over the past one month there was a price change of 15.89%. Year-to-date (YTD), TARS shares are showing a performance of 151.06% which increased to 206.45% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $15.60 but also hit the highest price of $52.99 during that period. The average intraday trading volume for Tarsus Pharmaceuticals Inc shares is 739.24K. The stock is currently trading 7.84% above its 20-day simple moving average (SMA20), while that difference is up 25.93% for SMA50 and it goes to 51.64% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) currently have 34.21M outstanding shares and institutions hold larger chunk of about 109.61% of that.
The stock has a current market capitalization of $1.94B and its 3Y-monthly beta is at 1.02. It has posted earnings per share of -$3.81 in the same period. It has Quick Ratio of 5.38 while making debt-to-equity ratio of 0.30. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TARS, volatility over the week remained 4.71% while standing at 6.40% over the month.
Stock’s fiscal year EPS is expected to rise by 29.65% while it is estimated to increase by 44.23% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on November 20, 2023 offering a Neutral rating for the stock and assigned a target price of $19 to it. Coverage by William Blair stated Tarsus Pharmaceuticals Inc (TARS) stock as an Outperform in their note to investors on July 18, 2023, suggesting a price target of $44 for the stock. On May 18, 2023, Guggenheim Initiated their recommendations, while on August 01, 2022, Barclays Initiated their ratings for the stock with a price target of $40. Stock get a Buy rating from H.C. Wainwright on December 21, 2021.
